Resultados de la búsqueda 21-30 of 13839 for Biochemistry

1. Hematología - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.

2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...

3. Untitled

   Page 1.

4. Hematología - Ensayos clínicos - Mayo Clinic

   ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...

5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...

6. Hematología - Ensayos clínicos - Mayo Clinic

   This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...

7. Hematología - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.

8. Hematología - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to determine the effectiveness and safety of JCAR017 in adult subjects with relapsed or refractory Chronic Lymphocytic Leukemia ( ...

9. Hematología - Ensayos clínicos - Mayo Clinic

   This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies displaying one of three different patterns ...

10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...